Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zolmitriptan
Drug ID BADD_D02393
Description Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan.[A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.[A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. It is currently available in both tablet and nasal spray forms.[L12978]
Indications and Usage Zolmitriptan is indicated for the acute treatment of migraine with or without auras in patients aged 18 and over.[L12978]
Marketing Status approved; investigational
ATC Code N02CC03
DrugBank ID DB00315
KEGG ID D00415
MeSH ID C089750
PubChem ID 60857
TTD Drug ID D0NG7O
NDC Product Code 64567-0016; 63548-0101; 64896-681; 64896-682; 64980-256; 68001-250; 72189-435; 65372-1145; 16571-803; 69238-2007; 65977-0050; 67835-5007; 64896-692; 65841-765; 65841-766; 64896-691; 64980-204; 69097-864; 71626-101; 72189-434; 65015-688; 46708-182; 64896-672; 68001-249; 68462-498; 60846-2384; 64896-671; 64980-203; 64980-257; 65841-768; 68382-715; 68462-497; 69097-863; 63548-0102; 63629-9575; 68382-712; 72606-567; 54864-955; 27241-022; 68382-717; 68462-499; 11722-012; 63850-4322; 45802-711; 46708-181; 46708-463; 55700-943; 55700-944; 68382-714; 69238-2006; 55111-800; 27241-021; 46708-462; 60846-2383; 65841-767; 65862-914; 65862-915; 68462-500; 71626-102; 72606-568; 65862-801; 66039-845; 16571-804
UNII 2FS66TH3YW
Synonyms zolmitriptan | 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone | Zomig | AscoTop | Zomigoro | 311C90 | Flezol
Chemical Information
Molecular Formula C16H21N3O2
CAS Registry Number 139264-17-8
SMILES CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.000677%
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.0070.001015%
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nausea07.01.07.0010.008394%
Neck pain15.03.04.009--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuropathy peripheral17.09.03.0030.000677%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophagitis07.08.05.001--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.001--Not Available
Osteoporosis15.02.03.002; 14.04.04.002--
Pain08.01.08.004--
Pain in extremity15.03.04.0100.002979%
Pain in jaw15.02.01.003--Not Available
Palpitations02.11.04.0120.002031%
Pancreatitis07.18.01.001--
Paraesthesia23.03.03.094; 17.02.06.0050.001015%
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Phenylketonuria20.02.01.018; 19.21.06.002; 17.03.07.002; 14.14.04.002; 03.08.04.002--Not Available
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 10 Pages